Year None2022202120202019201820172016 08-08-2022 Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results 08-02-2022 Pliant Therapeutics to Participate in BTIG Biotechnology Conference 07-21-2022 Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Primary Sclerosing Cholangitis 07-15-2022 Pliant Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares 07-12-2022 Pliant Therapeutics Announces Pricing of Upsized $200.0 Million Public Offering 07-11-2022 Pliant Therapeutics Announces Proposed Public Offering of Common Stock 07-10-2022 Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis 06-24-2022 Pliant Therapeutics Announces Presentations at the International Liver Congress™ 2022 Highlighting Preclinical and Clinical Data in Support of the INTEGRIS-PSC Phase 2a Clinical Trial 06-22-2022 Pliant Therapeutics Presents Preclinical Data Highlighting a Novel Approach for the Treatment of Muscular Dystrophies 06-16-2022 Pliant Therapeutics Announces Advancement of Integrin Target in Fibrosis Under Strategic Collaboration Pagination Current page 1 Page 2 Page 3 Next page next › Last page last »